share_log

艾美疫苗:自願性公告 - 四價結合流腦疫苗II期臨床試驗啟動

AIM VACCINE: VOLUNTARY ANNOUNCEMENT - INITIATION OF PHASE II CLINICAL TRIAL OF TETRAVALENT MENINGOCOCCAL CONJUGATE VACCINE

香港交易所 ·  Mar 3 18:54
Summary by Moomoo AI
艾美疫苗股份有限公司(「艾美疫苗」)於2024年3月2日宣布,旗下四價結合流腦疫苗II期臨床試驗已在雲南省疾病預防控制中心正式啟動。該試驗由保山市隆陽區疾病預防控制中心和大理州巍山彝族回族自治縣疾病預防控制中心作為研究現場。流行性腦脊髓膜炎是由奈瑟氏腦膜炎球菌引起的急性傳染病,艾美疫苗開發的四價結合疫苗旨在預防該病毒A群、C群、Y群和W135群。公司已完成相關疫苗生產車間建設,預計產品上市後將迎來廣闊市場。2023年全球腦膜炎結合疫苗銷售額達14.18億美元,艾美疫苗的新產品將有助於控制中國流腦疾病。董事會主席、執行董事兼首席執行官周延先生於2024年3月4日發布此消息。
艾美疫苗股份有限公司(「艾美疫苗」)於2024年3月2日宣布,旗下四價結合流腦疫苗II期臨床試驗已在雲南省疾病預防控制中心正式啟動。該試驗由保山市隆陽區疾病預防控制中心和大理州巍山彝族回族自治縣疾病預防控制中心作為研究現場。流行性腦脊髓膜炎是由奈瑟氏腦膜炎球菌引起的急性傳染病,艾美疫苗開發的四價結合疫苗旨在預防該病毒A群、C群、Y群和W135群。公司已完成相關疫苗生產車間建設,預計產品上市後將迎來廣闊市場。2023年全球腦膜炎結合疫苗銷售額達14.18億美元,艾美疫苗的新產品將有助於控制中國流腦疾病。董事會主席、執行董事兼首席執行官周延先生於2024年3月4日發布此消息。
AMIE VACCINES CO., LTD. (“AMY VACCINES”) ANNOUNCED ON MARCH 2, 2024 THAT A PHASE II CLINICAL TRIAL OF ITS FOUR-PRICE COMBINED CEREBRAL INFLUENZA VACCINE HAS BEEN OFFICIALLY LAUNCHED AT THE YUNNAN CENTER FOR DISEASE PREVENTION CONTROL. The trial was conducted by Baoshan Longyang District Disease Prevention Control Center and Dali State Weishan Yi Hui Autonomous County Disease Prevention Control Center as a research site. EPIDEMIC MENINGITIS IS AN ACUTE INFECTIOUS DISEASE CAUSED BY THE NETHER MENINGITIS COCCUS. THE QUADRUPLE COMBINATION VACCINE DEVELOPED BY EMERY IS DESIGNED TO PREVENT THE VIRUS FROM GROUP A, GROUP C, GROUP Y AND GROUP W135. The company has completed the construction of the relevant vaccine production workshop and expects that the product will reach a wide market once the product is launched. WITH GLOBAL MENINGITIS COMBINED VACCINE SALES OF US$14.18 BILLION IN 2023, EMERY'S NEW PRODUCTS WILL HELP CONTROL ENCEPHALOPAEMIA IN CHINA. Mr. Zhou Yan, Chairman of the Board, Executive Director and Chief Executive Officer, issued this announcement on March 4, 2024.
AMIE VACCINES CO., LTD. (“AMY VACCINES”) ANNOUNCED ON MARCH 2, 2024 THAT A PHASE II CLINICAL TRIAL OF ITS FOUR-PRICE COMBINED CEREBRAL INFLUENZA VACCINE HAS BEEN OFFICIALLY LAUNCHED AT THE YUNNAN CENTER FOR DISEASE PREVENTION CONTROL. The trial was conducted by Baoshan Longyang District Disease Prevention Control Center and Dali State Weishan Yi Hui Autonomous County Disease Prevention Control Center as a research site. EPIDEMIC MENINGITIS IS AN ACUTE INFECTIOUS DISEASE CAUSED BY THE NETHER MENINGITIS COCCUS. THE QUADRUPLE COMBINATION VACCINE DEVELOPED BY EMERY IS DESIGNED TO PREVENT THE VIRUS FROM GROUP A, GROUP C, GROUP Y AND GROUP W135. The company has completed the construction of the relevant vaccine production workshop and expects that the product will reach a wide market once the product is launched. WITH GLOBAL MENINGITIS COMBINED VACCINE SALES OF US$14.18 BILLION IN 2023, EMERY'S NEW PRODUCTS WILL HELP CONTROL ENCEPHALOPAEMIA IN CHINA. Mr. Zhou Yan, Chairman of the Board, Executive Director and Chief Executive Officer, issued this announcement on March 4, 2024.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more